Compare Quest Diagnostics Inc (DGX) vs SoFi Technologies Inc (SOFI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs SoFi Technologies Inc — how do they compare? Quest Diagnostics Inc trades at $205.45 (market cap $22.80B), while SoFi Technologies Inc trades at $18.67 (market cap $23.79B). The key difference: Quest Diagnostics Inc and SoFi Technologies Inc are close in size by market cap, and Quest Diagnostics Inc pays a 1.67% dividend while SoFi Technologies Inc pays none. Which is the better fit depends on your goals.
| DGX | SOFI | |
|---|---|---|
Market Cap | $22.80B | $23.79B |
Sector | Health | Financials |
52-Week High | $216.02 | $32.21 |
52-Week Low | $166.42 | $15.15 |
Enterprise Value | $28.82B | — |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
SoFi trades at $18.13, down 3.46% today but up from its year-to-date low near $15. The stock is in a bullish technical trend with key support at $18 and resistance at $19. Fundamentally, revenue grew to $3.61B in 2025 with net income of $481.32M, though cash flow from operations remains negative. Recent news highlights AI acquisitions and ETF launches as growth catalysts.
The outlook is mixed: analyst consensus targets $22.43 (24% upside) with 33% buy ratings, but risks include persistent negative operating cash flow and high P/E of 40.29. Earnings beats in recent quarters support growth narrative, yet profitability sustainability and interest rate sensitivity are key investor concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About SoFi Technologies Inc
SoFi is a financial services company that was founded in 2011 and is currently based in San Francisco. Initially known for its student loan refinancing business, the company has expanded its product offerings to include personal loans, credit cards, mortgages, investment accounts, banking services, and financial planning. The company intends to be a one-stop shop for its clients' finances and operates solely through its mobile app and website. Through its acquisition of Galileo in 2020 the company also offers payment and account services for debit cards and digital banking.
Read more on SOFI →
